Information provided on Forbes Advisor is for educational purposes only. Your financial situation is unique and the products and services we review may not be right for your circumstances. We do not ...

Biogen is looking to the future of its spinal muscular atrophy (SMA) business, taking an Ionis-partnered candidate that could offer dosing just once a year into pivotal trials on the strength of ...

Biotech company Zealand Pharma A/S, an innovator in peptide-based medicines, announced the positive topline results from its phase 3 trial of glepaglutide on Friday. A total of 106 patients with short ...